CD86 and melanoma: We investigated whether the use of a MART-1 expressing chimeric Ad5/3, targeting CD80 and CD86 on DCs, could result in efficient priming and activation of melanoma specific CD8+ T effector cells both in vitro and in a human ex vivo SLN model.